Ainostics

Executive Summary

Ainostics is a UK-based AI diagnostics company founded in 2019, focused on developing automated, multi-modal diagnostic tools for neurological disorders. Its flagship product, BR[AI]N, leverages structural MRI scans to predict conversion to Alzheimer’s disease, addressing a critical unmet need in early detection. The platform is built on over two decades of research, offering a scalable, AI-enabled solution that could significantly reduce diagnostic timelines and costs. Despite operating in a competitive landscape, Ainostics’ focus on tissue-modifying diseases and its extensible platform position it for potential partnerships and market adoption.

Upcoming Catalysts (preview)

• 2026CE Marking or FDA Clearance for BR[AI]N60% success
• 2026Publication of Prospective Clinical Validation Results70% success
• 2027Strategic Partnership with Pharma or Diagnostic Distributor50% success